What does this research mean for the field?

The rationally designed hybrid peptide Cec-Aur 1 exhibits potent anti-MRSA, anti-biofilm, and synergistic activities with oxacillin, alongside minimal toxicity and in vivo efficacy in reducing bacterial burden. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To design short hybrid antimicrobial peptides from Cecropin B and Aurein 1.2 and evaluate their antibacterial, antibiofilm, synergistic, and safety properties against MRSA.

September 5, 2026Scientific ReportsOpen Access

Rational design of short hybrid Cecropin B/Aurein 1.2 peptide analogues: in vitro synergistic anti-MRSA and anti-biofilm activities

View Full Paper

Ask AI

Bookmark

Authors

MGMaryam Ghahramani MAMohammad Aghazadeh JSJavid Sadeghi

Discussion

Member takes

Implication

Preclinical evaluation reveals that a hybrid Cecropin B/Aurein peptide combats MRSA biofilms and synergizes with oxacillin, suggesting a promising candidate for resistant wound infections.

Key Points

To design short hybrid antimicrobial peptides from Cecropin B and Aurein 1.2 and evaluate their antibacterial, antibiofilm, synergistic, and safety properties against MRSA.
Designed two hybrid peptides (Cec-Aur 1 and 2) using bioinformatics tools and evaluated MIC and MBC against five clinical MRSA isolates and reference strain ATCC 33591.
Tested Cec-Aur 1 synergy with oxacillin via checkerboard assays, alongside time-kill kinetics, biofilm inhibition, hemolysis, and cytotoxicity in HEK-293 and HDF cells.
Assessed in vivo therapeutic efficacy in a murine MRSA wound infection model.
Cec-Aur 1 showed geometric mean MIC and MBC values of 215 and 430 µg/mL against MRSA, producing concentration-dependent bactericidal action and dose-dependent biofilm inhibition.
Cec-Aur 1 demonstrated marked synergy with oxacillin, achieving fractional inhibitory concentration index values as low as 0.025 and up to a 64-fold reduction in oxacillin MIC.
Hemolysis was negligible and cell viability exceeded 80% in vitro, while in vivo treatment decreased wound bacterial burden by more than 93% and accelerated tissue healing.

Cite This Study

Ghahramani et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd3a66b95aff0620eac39 https://doi.org/10.1038/s41598-026-69666-1

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation reveals that a hybrid Cecropin B/Aurein peptide combats MRSA biofilms and synergizes with oxacillin, suggesting a promising candidate for resistant wound infections.

Rational design of short hybrid Cecropin B/Aurein 1.2 peptide analogues: in vitro synergistic anti-MRSA and anti-biofilm activities

Discussion

Member takes

Implication

Key Points

Cite This Study

Rational design of short hybrid Cecropin B/Aurein 1.2 peptide analogues: in vitro synergistic anti-MRSA and anti-biofilm activities

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider